Report an accessibility problem

Available to ASU Researchers— Sangre Por Salud (SPS) Biobank

Research Development
January 21, 2021

The Sangre Por Salud (SPS) Biobank was created as a research registry that is focused on enhancing research opportunities for Latino patients and promoting research collaborations around Latino health and health disparities.  Mayo Clinic partnered with Mountain Park Health Center (MPHC) to establish the SPS Biobank, a federally qualified health center in Phoenix, AZ that is committed to providing affordable, high-quality healthcare with an emphasis on five core services – family medicine, pediatric services, women’s healthcare, pharmacy and dental care.  MPHC’s mission is to work with the communities they serve to sustain and improve health by providing access to affordable primary care.  Therefore, through MPHC’s collaboration with Mayo Clinic, we developed the SPS Biobank, which has the current goals:

  • Develop a biobank that is connected to an electronic health record in order to facilitate translation of precision medicine initiatives into communities with health disparities
  • Facilitate biomedical research opportunities for Latino patients that receive care through MPHC
  • Encourage Mayo Clinic investigators to enroll Latino patients into research studies
  • Promote collaborative and transdisciplinary research projects focused on understanding and improving health among Latinos (types of projects can include: health disparity research, cross-sectional/prevalence studies, time trend or panel designs, prospective cohort studies, nested case-control studies using banked, pre-disease biospecimens and more)

SPS Biobank participants have provided a blood sample for DNA and serum/plasma research, completed a health questionnaire, and have allowed access to medical records.  Participants also consented for prospective follow-up for health outcomes, which will be ascertained through periodic contacts and linkages to the medical record and a separate SPS database.  Biobank participants have granted permission for future use (which is addressed in the informed consent) of their samples and information to address health-related research questions.

Enrollment into the SPS Biobank began in May of 2013 and ended September 2018 with a total number of 3,756 patients enrolled.  The SPS Biobank and MPHC patients is enriched in patients affected by obesity, prediabetes (as defined by the American Diabetes Association), and type 2 diabetes mellitus.

What’s available? 

  • Over 3,500 participants samples (including DNA, Serum, Plasma: EDTA, 50% platelet-poor and sodium citrate, White blood cells (buffy coat)) and data (including past, present and future electronic health records, self-reported data from participants on health, family health history and lifestyle factors known to confer risk of disease, genetic data including GWAS and DNA sequence data, as well as option to re-contact participants for additional data or studies).

What are the benefits of using the SPS Biobank? 

  • Fast access to high-quality samples and data, preliminary data for grant applications, and genotype-driven recruitment.

 

For more information about this Biobank, please contact Ashley Law, Manager, Strategic Partnerships at Ashley.f.law@asu.edu